Amgen Promotes Two Senior Executives: Names Brian McNamee Executive Vice President and Stuart Tross Senior Vice President Read more about Amgen Promotes Two Senior Executives: Names Brian McNamee Executive Vice President and Stuart Tross Senior Vice President
Amgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94 Read more about Amgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets Read more about Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Amgen Announces Webcast of 2013 Third Quarter Financial Results Read more about Amgen Announces Webcast of 2013 Third Quarter Financial Results
Amgen Announces Appointment Of Greg C. Garland To Board Of Directors Read more about Amgen Announces Appointment Of Greg C. Garland To Board Of Directors
Amgen Announces 2013 Fourth Quarter Dividend Read more about Amgen Announces 2013 Fourth Quarter Dividend
Amgen Presents Nearly Two Dozen Abstracts From Romosozumab And Prolia® (Denosumab) At ASBMR Read more about Amgen Presents Nearly Two Dozen Abstracts From Romosozumab And Prolia® (Denosumab) At ASBMR
Amgen And AstraZeneca Highlight Data To Be Presented At 22nd Congress Of The European Academy Of Dermatology And Venereology Read more about Amgen And AstraZeneca Highlight Data To Be Presented At 22nd Congress Of The European Academy Of Dermatology And Venereology
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer Read more about Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival Read more about Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival
